Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Alemtuzumab (Lemtrada) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study
Alemtuzumab (Lemtrada) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study
Alemtuzumab (Lemtrada) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study
Submitted by
admin
on October 22, 2011 - 12:30pm
Source:
Yahoo/BusinessWire
News Tags:
alemtuzumab
Lemtrada
Sanofi
Genzyme
multiple sclerosis
Headline:
Alemtuzumab (Lemtrada) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study
Do Not Allow Advertisers to Use My Personal information
